Sign In to Follow Application
View All Documents & Correspondence

A Nucleotide Sequence And A Process Thereof

Abstract: The present disclosure relates to a process of identification and isolation of sorbitol dehydrogenase promoter from Pichia pastoris. Further  the present disclosure also relates to expression of heterologous proteins under the control of Sorbitol dehydrogenase promoter in Pichia pastoris.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
10 October 2012
Publication Number
46/2015
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2020-06-16
Renewal Date

Applicants

BIOCON LIMITED
20th KM  Hosur Road  Electronic City P.O.  Bangalore – 560 100  Karnataka  India.

Inventors

1. NAGARAJ GOVINDAPPA
Nakshatra  #40  3rd Cross  Santosh Residency  Kadabagere  Bengaluru- 562 130  Karnataka  India.
2. SANKAR PERIYASAMY
65  Pudhuvelliyampalayam  Nathakadaiyur  Tirupur-638108  Tamil Nadu  India.
3. SHIVAKUMAR MADENAHALLI CHANNABASAPPA
“Anugraha”  # 4 (15)  2B main  3rd cross  MES Road  Muthyala Nagar  Gokula post  Bangalore 560054  Karnataka  India.
4. SUMA SREENIVAS
#67/1  7th Cross  Sampige Road  Malleswaram  Bengaluru-560 003  Karnataka  India.
5. KEDARNATH NANJUND SASTRY
77/A  2nd Cross  Banashankari  3rd Stage  3rd Phase  4th Block  Bengaluru-560085  Karnataka  India.

Specification

TECHNICAL FIELD
The present disclosure describes identification and isolation of sorbitol dehydrogenase promoter from P.pastoris and expression of heterologous protein in P.pastoris under the influence of said isolated promoter  specifically expression of Human Albumin (HA) and Erythrina Trypsin Inhibitor (ETI).

BACKGROUND AND PRIOR ART OF THE DISCLOSURE
Pichia pastoris is a very widely used well-established industrial host for producing therapeutic recombinant proteins. Production of therapeutic recombinant proteins poses several problems such as clipping at N-terminal (Prabha et.al. 2009) or C-terminal  introduction of desired glycoforms (Wouter Vervecken et.al. 2004). There is a need for enhancing the protein productivity and quality to meet the growing demands of the market and the growing regulatory issues on biosimilarities. This can be achieved by co-expressing the molecular chaperones (Wei Zhang et.al. 2006)  Co-expression of proteases to get the desired end product .In all these cases there is need for additional promoters for carrying out genetic manipulation to improve quality and quantity of the recombinant protein.

US Patent No. 6033898 discloses a DNA segment isolated from a Saccharomyces cerevisiae sorbitol dehydrogenase gene which is utilized to increase production of a heterologous polypeptide. US Patent No. 5 139 936 discloses a cloning vector containing a foreign gene and the yeast galactosidase (GAL1) regulatory region and promoter in position to increase expression of the foreign gene. US Patent No. 5 089 398 discloses the use of the promoter region from the glyceraldehyde-3-phosphate dehydrogenase to control expression of a foreign polypeptide in yeast.

Although several promoters  either constitutive or inducible are available for the Pichia expression system  AOX1 is employed in most studies and application. AOX1 promoter is a strong inducible promoter and has tight regulation by carbon sources  expression is highly repressed when Pichia pastoris is grown in the presence most of other carbon sources other than Methanol. Methanol is an inducer of AOX1 promoter  methanol is a hazardous substance due to its high flammability and toxicity  also the cells growing on methanol have a very high oxygen consumption which usually requires addition of pure oxygen to the culture  thus increasing the cost of the process and limiting the cultivation capacity at large scale (Monika Bollok et.al.  Recent Patents on biotechnology  3(2009) 192-201.)
Also host cellular protein (HCP) release from P.pastoris grown on methanol is high which is mainly derived during cell lysis but it occurs to a much lower extent upon growth with glucose as a carbon source. As a result cells maintain higher viability and higher purity of the secreted protein.
Futher  the sorbitol dehydrogenase promoter identified in S.cerevisiae is 750bps. Due to large base pair size  it is not so easy to carry out genetic manipulation as it leads to increase of the vector size. The instant disclosure aims at overcoming the issues mentioned above. Also  there is a need in the art to identify more promoters for the expression of heterologous recombinant proteins in Pichia pastoris which does not require any specific induction for expression of protein.

SUMMARY OF THE DISCLOSURE
Accordingly  the present disclosure relates to a nucleotide sequence set forth as SEQ ID No.1; a process of isolation of SEQ ID No.1  said process comprising acts of- a) isolating genomic DNA from P.pastoris  b)amplifying a region comprising SEQ ID No.1 within the isolated genomic DNA  and c) subjecting the amplified product to a conventional gel elution procedure to isolate said SEQ ID No.1; a process of expressing a gene under regulation of SEQ ID No.1 in a medium comprising non-specific inducer  said process comprising acts of-a) cloning said gene in an expression construct downstream to the SEQ ID No.1  b) transforming a host with the expression construct  and c) expressing the gene under the regulation of said SEQ ID No.1 in a medium comprising non-specific inducer for production of hetrologous protein; a vector comprising the nucleotide sequence as mentioned above; a transformed host cell comprising the vector as mentioned above.
BRIEF DESCRIPTION OF ACCOMPANYING FIGURES
Figure 1 shows restriction analysis of SDPHA/pMBL208. All the digestions results in the expected pattern.
Figure 2 shows vector map of SDPHA/pMBL208.
Figure 3 shows screening of colonies for selecting high producer of recombinant protein on G418 antibiotic. The colony shown in the arrow indicates the higher resistant clone.
Figure 4 shows PCR confirmation of the integrated gene into the P.pastoris genome. All the clones selected are found to have the gene of interest.
Figure 5 shows expression analysis of HA when grown using sorbitol as a sole carbon source.
Figure 6 shows expression analysis of HA when grown using methanol as a sole carbon source.
Figure 7 shows expression analysis of HA when grown using glucose as a sole carbon source.
Figure 8 shows expression analysis of cell free suprnatant without any induction (cells are grown in expansion medium).
Figure 9 shows Picture of ETI expression constructs; A) ETI is cloned in the XhoI and E.coRI restriction sites under the control of sorbitol dehydrogenase promoter. B) ETI with no promoter upstream.
Figure 10 shows expression analysis of ETI when grown using sorbitol as a sole carbon source.
Figure 11 shows determination of ETI productivity under different carbon sources.

DETAILED DESCRIPTION OF DISCLOSURE
The present disclosure relates to a nucleotide sequence set forth as SEQ ID No. 1.
In an embodiment of the present  said nucleotide sequence is sorbitol dehydrogenase promoter.
In another embodiment of the present disclosure  said nucleotide sequence is identified and isolated from P.pastoris.
The present disclosure relates to a process of isolation of SEQ ID No.1  said process comprising acts of: a) isolating genomic DNA from P.pastoris  b) amplifying a region comprising SEQ ID No.1 within the isolated genomic DNA  and c) subjecting the amplified product to a conventional gel elution procedure to isolate said SEQ ID No.1.
In an embodiment of the present disclosure  the amplification of SEQ ID No.1 is carried out by forward primer set forth as SEQ ID No.2 and reverse primer set forth as SEQ ID No.3.
The present disclosure relates to a process of expressing a gene under regulation of SEQ ID No.1 in a medium comprising non-specific inducer  said process comprising acts of: a) cloning said gene in an expression construct downstream to the SEQ ID No.1  b) transforming a host with the expression construct  and c) expressing the gene under the regulation of said SEQ ID No.1 in a medium comprising non-specific inducer for production of hetrologous protein.
In an embodiment of the present disclosure  said host is methylotrophic yeast  preferably P.pastoris.
In another embodiment of the present disclosure  said heterologous protein is selected from a group comprising human albumin and erythrina trypsin inhibitor.
In yet another embodiment of the present disclosure  said expression is carried out by a non-specific inducer.
In still another embodiment of the present disclosure  said non-specific inducer selected from a group comprising sorbitol  glucose  glycerol  fructose  mannitol  lactic acid  sucrose  starch  methanol or any combination thereof.
The present disclosure relates to a vector comprising the nucleotide sequence as mentioned above.
The present disclosure relates to a transformed host cell comprising the vector as mentioned above.
The present disclosure relates to identification of sorbitol dehydrogenase promoter as a potential tool to express heterologous recombinant proteins in P.pastoris that does not require any specific induction for expression.

In an embodiment of the present disclosure  210bps promoter is located on the chromosome 1 of P.pastoris.

In another embodiment of the present disclosure  sortibol dehydrogenase promoter is the smallest promoter in P.pastoris.

In an embodiment of the present disclosure  promoter region available upstream of Sorbitol dehydrogenase gene is identified to have CAAT and GC boxes within that region.

In another embodiment of the present disclosure  the promoter is successfully used to express recombinant proteins such as Human Albumin (HA) and Erythrina Trypsin Inhibitor (ETI).
In another embodiment of the present disclosure  the heterlogous proteins such as human albumin and erythrina trypsin inhibitor are expressed under the control of sorbitol dehydrogenase promoter.

In another embodiment of the present disclosure  the sorbitol dehydrogenase promoter enables the expression of heterlogous proteins under any type of carbon source.

In another embodiment of the present disclosure  the sorbitol dehydrogenase promoter enables the expression of heterlogous protein utilizing sorbitol  glucose  glycerol  fructose  mannitol  lactic acid  sucrose  starch and methanol as a carbon source.

In another embodiment of the present disclosure  the sorbitol dehydrogenase gene from P.pastoris is identified by the following process: a) Sorbitol dehydrogenase gene orthologs is subjected to NCBI blast which resulted in multiple hits; b) identifying sorbitol dehydrogenase gene in Pichia pastoris located on the chromosome 1  and; c) analysing the sequence upstream of the identified sorbitol dehydrogenase gene.

In another embodiment of the present disclosure  expression of a target gene to obtain a protein of interest under the influence of the chimeric promoter of the instant invention is not limited by the carbon source being employed. In other words  by making use of the chimeric promoter of this invention  the protein of interest may be expressed by making use of any carbon source such as but not limited to sorbitol  glucose  glycerol  fructose  mannitol  lactic acid  sucrose . However  a person skilled in the art will recognize the most potent inducers for higher expression of a specific type of protein and hence will be able to employ any inducer having such high potency or likeliness of higher expression than the remaining inducers.
In another embodiment of the present disclosure the term non-specific inducer and carbon source is used interchangeably in accordance to the description.
In another embodiment of the present disclosure  recombinant expression system is selected from prokaryotic and eukaryotic hosts. Eukaryotic hosts include yeast cells (e.g.  Saccharomyces cerevisiae or Pichia pastoris)  mammalian cells or plant cells. Bacterial and eukaryotic cells are available from a number of different sources including commercial sources to those skilled in the art  e.g.  the American Type Culture Collection (ATCC; Rockville  Md.). Commercial sources of cells used for recombinant protein expression also provide instructions for usage of the cells. The choice of the expression system depends on the features desired for the expressed polypeptide.
In another embodiment of the present disclosure  the most preferred host cells are methylotrophic yeasts. Strains of a methylotrophic yeast which can be modified using the present disclosure include  but are not limited to yeast strains capable of growing on methanol  such as yeasts of the genera Pichia  Candida  Hansenula  or Torulopsis. Preferred methylotrophic yeasts are of the genus Pichia. Methylotrophic yeast strains which can be modified using the present methods also include those methylotrophic yeast strains which have been engineered to express one or more heterologous proteins of interest.
In another embodiment of the present disclosure  the term “promoter” is used in the normal sense of the art  e.g. an RNA polymerase binding site. The term “vector” includes expression vectors  replicable vectors  transformation vectors and shuttle vectors  including vector combinations thereof.
In another embodiment of the present disclosure  the term “expression vector” means a construct capable of in-vivo or in-vitro expression.
In another embodiment of the present disclosure  preferentially the expression vector is incorporated in the genome of the organism. The term “incorporated” preferably covers stable incorporation into the genome.
In another embodiment of the present disclosure  "expressing polypeptides" is meant as expression of DNA sequences encoding the polypeptide. "Polypeptides" are polymers of [alpha]-amino acids which are covalently linked through peptide bonds. Polypeptides include low molecular weight polymers as well as high molecular weight polymers more commonly referred to as proteins. In addition  a polypeptide can be a phosphopolypeptide  glycopolypeptide or metallopoly-peptide. Further  one or more polymer chains may be combined to form a polypeptide. As used herein a "heterologous polypeptide" is a polypeptide which is not normally expressed and secreted by the filamentous fungus used to express that particular polypeptide. Heterologous polypeptides include polypeptides derived from prokaryotic sources (e.g.  [alpha]-amylase from Bacillus species  alkaline protease from Bacillus species  and various hydrolytic enzymes from Pseudomonas  etc.)  polypeptides derived from eukaryotic sources (e.g.  bovine chymosin  human tissue plasminogen activator  human growth hormone  human interferon  urokinase  human serum albumin  factor VIII etc.)  and polypeptides  derived from fungal sources other than the expression host (e.g.  glucoamylase from A.niger and Heterologous polypeptides also include hybrid polypeptides which comprise a combination of partial or complete polypeptide sequences derived from at least two different polypeptides each of which may be homologous or heterologous with regard to the fungal expression host. Examples of such hybrid polypeptides include: 1) DNA sequences encoding prochymosin fused to DNA sequences encoding the A.niger glucoamylase signal and pro sequence alone or in conjunction with various amounts of amino-terminal mature glucoamylase codons  and 2) DNA sequences encoding fungal glucoamylase or any fungal carboxy protease  human tissue plasminogen activator or human growth hormone fused to DNA sequences encoding a functional signal sequence alone or in conjunction with various amounts of amino-terminal propeptide condons or mature codons associated with the functional signal.
The invention is further illustrated by the following examples. The following examples are provided for illustrative purposes only and are not intended to limit the scope of the invention.
EXAMPLES
Example1: Pichia pastoris Sorbitol dehydrogenase Promoter (SDP) Isolation and Cloning

The coding sequence of sorbitol dehydrogenase gene is identified  which is located on chromosome no. 1 of P.pastoris. The region upstream to 5` region to the coding sequence of the identified gene is examined. The examined gene is identified as a promoter region for Sorbitol dehydrogenase comprising 210bp. The genomic DNA of P.pastoris is isolated using the conventional gene isolation technique. The isolated gene is subjected to polymerase chain reaction to amplify the examined 210bp region.

The primers used to amplify the examined gene are-
SORFP= 5’ AGA TAT CAA GTT GTA TAT TAT TAA TGG CGG GGC A 3’ (EcoRV at 5’ end)
SORRP = 5’ TCA TAT GTT GGA TAA TAG TGA GTG TAA TGA 3’ (NdeI at 5’ end).

The below chromatogram shows the sequencing results obtained for sorbitol dehydrogenase promoter isolated from P.pastoris. The promoter region from the region 37 to 246 bp is highlighted within brackets.

The amplicon is subjected to agarose gel electrophoresis against a suitable marker. The amplified 210bp region on the gel is eluted using Qiagen spin columns. The gel purified product is A-tailed under the polymerase chain reaction. The A-tailed PCR product is ligated to TA vector (pTZ57R) at 16ºC  overnight. The ligated product is transformed to E coli DH5a by heat shock method and plated on LBA100 and incubated the plates at 37 °C overnight.
Example 2: Cloning and restriction analysis of SDPHA/pMBL208

The plasmid pMBL208 having human albumin gene (HA) with an AOX1 promoter is selected. The AOX1 promoter is removed from rHA/pMBL His plasmid by digesting it with EcoRV and NdeI restriction enzymes. Same restriction enzymes are used to release the sorbitol dehydrogenase promoter (SDP) from pTZ57R. The released SDP is ligated to the AOX1 removed vector (fig 2). The ligated product is transformed to E coli DH5a and plated on LBA100  plates are incubated overnight at 37°C  and the transformed colonies are screened for correct plasmid by colony PCR. The positive clone is isolated and inoculated in Luria Broth (LB) and grown overnight at 37 °C to isolate plasmid  plasmid is isolated from overnight grown culture using Qiagen mini prep spin columns. Isolated plasmid is confirmed by restriction digestion (fig.1) with the following restriction enzymes- EcoRV and NdeI  EcoRV and EcoRI  EcoRI and NdeI and EcoRV.

Example 3: Transformation of P.pastoris with SDPHA/pMBL208.

The plasmid SDPHA/pMBL208 is linearized with EcoRV and transformed to P.pastoris. The transformed cells are spread on to Yeast nitrogen base (YNB) agar plates without any amino acids for selection. The plates are incubated at 30°C for two days till the colonies appear.
Example 4: Screening of colonies for higher Geneticin (G418) resistance.

Upon observing growth of the colonies in YNB agar plates  the colonies are picked and inoculated into Yeast Extract Peptone Dextrose (YPD) in 96-well plate and incubated at 30°C  overnight. The cultures from 96-well plate are stamped onto YPD agar plates containing 0.5mg/ml of G418 and incubated the plated at 30°C for 2 days. After 2 days the colonies showing higher resistance to G418 are selected and streaked onto YPD agar plates as shown in fig. 3. The colony shown in the arrow indicates the higher resistant clone.
The clones selected based on their resistance to G418 are: 3G11  4F11  5F5  6F10  4B1  4F10  5A1  7A10. From these selected clones  the genomic DNA is isolated by the Phenol Chloroform Method. The vector SDPHA/pMBL208 recombination is confirmed by PCR using the primers SORFP and HSAintRP. This gives amplification of about 750 bps (fig 4). Figure 4 represents a gel for the PCR confirmation of the integrated gene into the P.pastoris genome for the clones 3G11  4F11  5F5  6F10  4B1  4F10  5A1  7A10 and it was observed that all the clones had proper intergration of gene in to the host genome.
Example 5: Expression Studies in SDPHA/ P.pastoris.

The shake flask induction studies is carried out for 4 selected clones (5F5  6F10  5A1 and 7A10) to find out whether the sorbitol promoter is able to produce human albumin (HA). The cell mass is developed and induction is carried out with three carbon sources such as Glucose  Methanol and Sorbitol. The shake flask induction samples are analysed using SDS PAGE  which is depicted in figures 5  6  7 and 8. Figure 5 represents the expression of Human albumin when cells are grown in the medium comprising sorbitol as a carbon source  wherein lane 1 relates to a protein molecular marker  lane 2 relates to Pichia pastoris with the sorbitol dehydrogenase promoter  lane 3  4  5  and 6 relates to HA in clones 5F5  6F10  5A1 and 7A10  respectively. Similarly  figures 6  7 relate to the expression of HA protein in Pichia pastoris when the cells are grown in the medium comprising methanol and glucose  respectively. Figure 8 relates to expression analysis of cell free supernatant for the clones 5F5  6F10  5A1 and 7A10  where cells are grown in expansion medium without any induction
Results and conclusion:
a) The level of HA expression is good and it is found to be similar with all three carbon sources; sorbitol  methanol and glucose. The SDS PAGE band intensity obtained in all cases is equivalent to or more than 2µgs  such band intensity is considered good expression.
b) Expression is observed during cell mass accumulation.
c) It also shows that the expression levels are increasing in dose dependent manner as it increases according to the higher G418 resistance as clone 5F5 is highest and 7A10 is the least among the clones selected.
Example 6: Expression of Erythrina Trypsin Inhibitor

In an attempt to find out the robustness of the Sorbitol dehydrogenase promoter for more number of heterologous protein expressions  Erythrina Trypsin Inhibitor (ETI) is been chosen. ETI is a small protein of ~20 KDa and it is useful for the affinity purification of Retaplase. The vector SDPHA/pMBL208 is digested with XhoI and EcoRI to remove HA gene from the vector. Synthetic ETI gene is subcloned into pMBL208 in place of HA gene. The ligated product is transformed to E coli DH5a and plated on LBA100  plates are incubated overnight at 37°C and the transformed colonies are screened for correct plasmid by colony PCR. The positive clone is isolated and inoculated in Luria Broth (LB) and grown overnight at 37 °C to isolate plasmid. The plasmid is isolated from overnight grown culture using Qiagen mini prep spin columns. Isolated plasmid is confirmed by restriction digestion with the following restriction enzymes- EcoRV/NdeI  EcoRV/ EcoRI  EcoRI/NdeI and EcoRV. ETI gene is cloned into pMBL208 with and without sorbitol dehydrogenase promoter (fig.9A and 9B). By doing so it is demonstrated that the production of ETI is due to the 210 bps sorbitol promoter and not because of any upstream promoter activity.
Example 7: Shake flask expression studies

The plasmid SDPETI/pMBL208 is linearized with EcoRV and transformed to P.pastoris. The transformed cells are spread on to Yeast nitrogen base (YNB) agar plates without any amino acids for selection. The plates are incubated at 30°C for two days till the colonies appear. Upon observing growth of the colonies in YNB agar plates  the colonies are picked and inoculated into Yeast Extract Peptone Dextrose (YPD) in 96-well plate and incubated at 30°C  overnight. The cultures from 96-well plate are stamped onto YPD agar plates containing 0.5mg/ml of G418 and incubated the plated at 30°C for 2 days. After 2 days the colonies showing higher resistance to G418 are selected and streaked onto YPD agar plates.
The clones selected based on the higher resistant to G418 are clones 1  2  3 and 4  these clones are inoculated into shake flask containing medium  expression of ETI in shake flask is analysed on 12% SDS PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). Productivity of expressed ETI under different carbon sources is shown in fig 10 and 11  the arrow mark shows the expressed ETI on the gel.
Results and conclusion:
Sorbitol dehydrogenase promoter is able to produces 20kDa ETI when grown in any of the carbon sources such as sorbitol  glucose  glycerol  fructose  mannitol  sucrose  lactic acid  starch and methanol. No expression is found without the sorbitol promoter upsetream of ETI. The productivity of the expressed protein is found to be higher when Glycerol is used as a carbon source. Lactic acid also is been able to produce ETI when compared to other saccharides such as monosaccharide  disaccharide and polysaccharides when used as a carbon source.
A Comparative Expression status for the heterologous protein produced under the influence of Sorbitol dehydrogenase promoter is shown in table 1 below.
Construct integrated into the Pichia pastoris genome Inducer/carbon source Expression status
Parent Pichia pastoris host Methanol No
ETI/pMBL208 (ETI CDS without SDP) Methanol No
SDPETI/pMBL208 (ETI CDS under SDP regulation) Methanol Yes
SDPETI/pMBL208 (ETI CDS under SDP regulation) Glucose Yes
SDPETI/pMBL208 (ETI CDS under SDP regulation Sorbitol Yes
SDPETI/pMBL208 (ETI CDS under SDP regulation Glycerol Yes
SDPHA/pMBL208 (Human albumin under SDP regulation) Methanol Yes
SDPHA/pMBL208 (Human albumin under SDP regulation) Glucose Yes
SDPHA/pMBL208 (Human albumin under SDP regulation) Sorbitol Yes
SDPHA/pMBL208 (Human albumin under SDP regulation) Glycerol Yes


SEQUENCE LISTING

<110> BANGALORE
BIOCON LIMITED

<120> A NUCLEOTIDE SEQUENCE AND A PROCESS THEREOF

<130> IP21406

<160> 3

<170> PatentIn version 3.5

<210> 1
<211> 213
<212> DNA
<213> Pichia pastoris

<400> 1
aagttgtata ttattaatgg cggggcagaa tgctctcagt ctcaactttt gatgattgcc 60

gggattaaaa aatcatgcac accggaaaaa cttatcccaa atgtatgtac cccacgtaat 120

ccgttgtagt tccaccaaag aatttaaaac gtacttcccg cccaataatc tgttcccttt 180

cccgcttcat tacactcact attatccaac atg 213

<210> 2
<211> 34
<212> DNA
<213> Pichia pastoris

<220>
<221> primer_bind
<222> (1)..(34)

<400> 2
agatatcaag ttgtatatta ttaatggcgg ggca 34

<210> 3
<211> 30
<212> DNA
<213> Pichia pastoris

<220>
<221> primer_bind
<222> (1)..(30)

<400> 3
tcatatgttg gataatagtg agtgtaatga 30



We Claim:
1. A nucleotide sequence set forth as SEQ ID No. 1.
2. The nucleotide sequence as claimed in claim 1  wherein said nucleotide sequence is sorbitol dehydrogenase promoter.
3. The nucleotide sequence as claimed in claim 1  wherein said nucleotide sequence is identified and isolated from P.pastoris.
4. A process of isolation of SEQ ID No.1  wherein said process comprising acts of:
a) isolating genomic DNA from P.pastoris;
b) amplifying a region comprising SEQ ID No.1 within the isolated genomic DNA; and
c) subjecting the amplified product to a conventional gel elution procedure to isolate said SEQ ID No.1.
5. The process as claimed in claim 4  wherein the amplification of SEQ ID No.1 is carried out by forward primer set forth as SEQ ID No.2 and reverse primer set forth as SEQ ID No.3.
6. A process of expressing a gene under regulation of SEQ ID No.1 in a medium comprising non-specific inducer  wherein said process comprising acts of:
a) cloning said gene in an expression construct downstream to the SEQ ID No.1;
b) transforming a host with the expression construct; and
c) expressing the gene under the regulation of said SEQ ID No.1 in a medium comprising non-specific inducer for production of hetrologous protein.
7. The process as claimed in claim 6  wherein said host is methylotrophic yeast  preferably P.pastoris.
8. The process as claimed in claim 6  wherein said heterologous protein is selected from a group comprising human albumin and erythrina trypsin inhibitor.
9. The process as claimed in claim 6  wherein said expression is carried out by a non-specific inducer.
10. The process as claimed in claim 6  wherein the non-specific inducer selected from a group comprising sorbitol  glucose  glycerol  fructose  mannitol  lactic acid  sucrose  starch  methanol or any combination thereof.

11. A vector comprising the nucleotide sequence as claimed in claim 1.
12. A transformed host cell comprising the vector as claimed in claim 11.

Documents

Orders

Section Controller Decision Date

Application Documents

# Name Date
1 338560-Form 27.pdf 2023-11-20
1 Form-5.pdf 2012-10-12
2 4231-CHE-2012-Correspondence_Form-27_19-08-2022.pdf 2022-08-19
2 Form-3.pdf 2012-10-12
3 Form-1.pdf 2012-10-12
3 4231-CHE-2012-Form 27_Statement of Working(Authorization Certificate)_19-08-2022.pdf 2022-08-19
4 Drawings.pdf 2012-10-12
4 4231-CHE-2012-Form 27_Statement of Working_19-08-2022.pdf 2022-08-19
5 4231-CHE-2012-FORM-26 [16-09-2020(online)].pdf 2020-09-16
5 4231-CHE-2012 FORM-18 12-10-2012.pdf 2012-10-12
6 4231-CHE-2012-PROOF OF ALTERATION [15-09-2020(online)].pdf 2020-09-15
6 4231-CHE-2012 FORM 3 17-12-2012.pdf 2012-12-17
7 4231-CHE-2012-Abstract_Granted 338560_16-06-2020.pdf 2020-06-16
7 4231-CHE-2012 Correspondence 17-12-2012.pdf 2012-12-17
8 4231-CHE-2012-Claims_Granted 338560_16-06-2020.pdf 2020-06-16
8 4231-CHE-2012 POWER OF ATTORNEY 18-12-2012.pdf 2012-12-18
9 4231-CHE-2012 FORM-3 18-12-2012.pdf 2012-12-18
9 4231-CHE-2012-Description_Granted 338560_16-06-2020.pdf 2020-06-16
10 4231-CHE-2012 CORRESPONDENCE OTHERS 18-12-2012.pdf 2012-12-18
10 4231-CHE-2012-Drawings_Granted 338560_16-06-2020.pdf 2020-06-16
11 4231-CHE-2012 CORRESPONDENCE OTHERS 05-03-2013.pdf 2013-03-05
11 4231-CHE-2012-IntimationOfGrant16-06-2020.pdf 2020-06-16
12 4231-CHE-2012 FORM-1 05-03-2013.pdf 2013-03-05
12 4231-CHE-2012-Marked up Claims_Granted 338560_16-06-2020.pdf 2020-06-16
13 4231-CHE-2012 OTHERS 20-06-2013.pdf 2013-06-20
13 4231-CHE-2012-PatentCertificate16-06-2020.pdf 2020-06-16
14 4231-CHE-2012 CORRESPONDENCE OTHERS 20-06-2013.pdf 2013-06-20
14 Correspondence by Agent_ Notarized Assignment_24-04-2019.pdf 2019-04-24
15 4231-CHE-2012 FORM 3 15-04-2015.pdf 2015-04-15
15 4231-CHE-2012-Annexure (Optional) [17-04-2019(online)].pdf 2019-04-17
16 4231-CHE-2012 FORM 3 19-08-2015.pdf 2015-08-19
16 4231-CHE-2012-Response to office action (Mandatory) [17-04-2019(online)].pdf 2019-04-17
17 4231-CHE-2012-FER.pdf 2017-07-19
17 4231-CHE-2012-Annexure (Optional) [28-03-2019(online)].pdf 2019-03-28
18 4231-CHE-2012-FORM 3 [28-03-2019(online)].pdf 2019-03-28
18 4231-CHE-2012-OTHERS [18-01-2018(online)].pdf 2018-01-18
19 4231-CHE-2012-FORM 3 [18-01-2018(online)].pdf 2018-01-18
19 4231-CHE-2012-Information under section 8(2) (MANDATORY) [28-03-2019(online)].pdf 2019-03-28
20 4231-CHE-2012-FER_SER_REPLY [18-01-2018(online)].pdf 2018-01-18
20 4231-CHE-2012-Written submissions and relevant documents (MANDATORY) [28-03-2019(online)].pdf 2019-03-28
21 4231-CHE-2012-DRAWING [18-01-2018(online)].pdf 2018-01-18
21 4231-che-2012-ExtendedHearingNoticeLetter_13Mar2019.pdf 2019-02-18
22 4231-CHE-2012-CORRESPONDENCE [18-01-2018(online)].pdf 2018-01-18
22 4231-CHE-2012-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [11-02-2019(online)].pdf 2019-02-11
23 4231-CHE-2012-COMPLETE SPECIFICATION [18-01-2018(online)].pdf 2018-01-18
23 Correspondence by Agent_Form26_11-02-2019.pdf 2019-02-11
24 4231-CHE-2012-FORM-26 [05-02-2019(online)].pdf 2019-02-05
24 4231-CHE-2012-CLAIMS [18-01-2018(online)].pdf 2018-01-18
25 4231-CHE-2012-ABSTRACT [18-01-2018(online)].pdf 2018-01-18
25 4231-CHE-2012-HearingNoticeLetter.pdf 2019-01-22
26 4231-CHE-2012-ABSTRACT [18-01-2018(online)].pdf 2018-01-18
26 4231-CHE-2012-HearingNoticeLetter.pdf 2019-01-22
27 4231-CHE-2012-CLAIMS [18-01-2018(online)].pdf 2018-01-18
27 4231-CHE-2012-FORM-26 [05-02-2019(online)].pdf 2019-02-05
28 4231-CHE-2012-COMPLETE SPECIFICATION [18-01-2018(online)].pdf 2018-01-18
28 Correspondence by Agent_Form26_11-02-2019.pdf 2019-02-11
29 4231-CHE-2012-CORRESPONDENCE [18-01-2018(online)].pdf 2018-01-18
29 4231-CHE-2012-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [11-02-2019(online)].pdf 2019-02-11
30 4231-CHE-2012-DRAWING [18-01-2018(online)].pdf 2018-01-18
30 4231-che-2012-ExtendedHearingNoticeLetter_13Mar2019.pdf 2019-02-18
31 4231-CHE-2012-FER_SER_REPLY [18-01-2018(online)].pdf 2018-01-18
31 4231-CHE-2012-Written submissions and relevant documents (MANDATORY) [28-03-2019(online)].pdf 2019-03-28
32 4231-CHE-2012-FORM 3 [18-01-2018(online)].pdf 2018-01-18
32 4231-CHE-2012-Information under section 8(2) (MANDATORY) [28-03-2019(online)].pdf 2019-03-28
33 4231-CHE-2012-FORM 3 [28-03-2019(online)].pdf 2019-03-28
33 4231-CHE-2012-OTHERS [18-01-2018(online)].pdf 2018-01-18
34 4231-CHE-2012-Annexure (Optional) [28-03-2019(online)].pdf 2019-03-28
34 4231-CHE-2012-FER.pdf 2017-07-19
35 4231-CHE-2012-Response to office action (Mandatory) [17-04-2019(online)].pdf 2019-04-17
35 4231-CHE-2012 FORM 3 19-08-2015.pdf 2015-08-19
36 4231-CHE-2012 FORM 3 15-04-2015.pdf 2015-04-15
36 4231-CHE-2012-Annexure (Optional) [17-04-2019(online)].pdf 2019-04-17
37 4231-CHE-2012 CORRESPONDENCE OTHERS 20-06-2013.pdf 2013-06-20
37 Correspondence by Agent_ Notarized Assignment_24-04-2019.pdf 2019-04-24
38 4231-CHE-2012 OTHERS 20-06-2013.pdf 2013-06-20
38 4231-CHE-2012-PatentCertificate16-06-2020.pdf 2020-06-16
39 4231-CHE-2012 FORM-1 05-03-2013.pdf 2013-03-05
39 4231-CHE-2012-Marked up Claims_Granted 338560_16-06-2020.pdf 2020-06-16
40 4231-CHE-2012 CORRESPONDENCE OTHERS 05-03-2013.pdf 2013-03-05
40 4231-CHE-2012-IntimationOfGrant16-06-2020.pdf 2020-06-16
41 4231-CHE-2012 CORRESPONDENCE OTHERS 18-12-2012.pdf 2012-12-18
41 4231-CHE-2012-Drawings_Granted 338560_16-06-2020.pdf 2020-06-16
42 4231-CHE-2012 FORM-3 18-12-2012.pdf 2012-12-18
42 4231-CHE-2012-Description_Granted 338560_16-06-2020.pdf 2020-06-16
43 4231-CHE-2012 POWER OF ATTORNEY 18-12-2012.pdf 2012-12-18
43 4231-CHE-2012-Claims_Granted 338560_16-06-2020.pdf 2020-06-16
44 4231-CHE-2012 Correspondence 17-12-2012.pdf 2012-12-17
44 4231-CHE-2012-Abstract_Granted 338560_16-06-2020.pdf 2020-06-16
45 4231-CHE-2012-PROOF OF ALTERATION [15-09-2020(online)].pdf 2020-09-15
45 4231-CHE-2012 FORM 3 17-12-2012.pdf 2012-12-17
46 4231-CHE-2012-FORM-26 [16-09-2020(online)].pdf 2020-09-16
46 4231-CHE-2012 FORM-18 12-10-2012.pdf 2012-10-12
47 Drawings.pdf 2012-10-12
47 4231-CHE-2012-Form 27_Statement of Working_19-08-2022.pdf 2022-08-19
48 Form-1.pdf 2012-10-12
48 4231-CHE-2012-Form 27_Statement of Working(Authorization Certificate)_19-08-2022.pdf 2022-08-19
49 Form-3.pdf 2012-10-12
49 4231-CHE-2012-Correspondence_Form-27_19-08-2022.pdf 2022-08-19
50 338560-Form 27.pdf 2023-11-20
50 Form-5.pdf 2012-10-12
51 338560-Form 27-240925.pdf 2025-09-25

Search Strategy

1 Search_11-07-2017.pdf

ERegister / Renewals

3rd: 28 Aug 2020

From 10/10/2014 - To 10/10/2015

4th: 28 Aug 2020

From 10/10/2015 - To 10/10/2016

5th: 28 Aug 2020

From 10/10/2016 - To 10/10/2017

6th: 28 Aug 2020

From 10/10/2017 - To 10/10/2018

7th: 28 Aug 2020

From 10/10/2018 - To 10/10/2019

8th: 28 Aug 2020

From 10/10/2019 - To 10/10/2020

9th: 28 Aug 2020

From 10/10/2020 - To 10/10/2021

10th: 02 Sep 2021

From 10/10/2021 - To 10/10/2022

11th: 04 Oct 2022

From 10/10/2022 - To 10/10/2023

12th: 04 Oct 2023

From 10/10/2023 - To 10/10/2024

13th: 11 Sep 2024

From 10/10/2024 - To 10/10/2025

14th: 22 Aug 2025

From 10/10/2025 - To 10/10/2026